US biotech royalty firm XOMA Royalty (Nasdaq: XOMA) has expanded its interest in mezagitamab, an anti-CD38 monoclonal antibody in Phase III development, through a deal worth up to $30 million with ...

The FDA has accepted for Priority Review the BLA for sibeprenlimab for the treatment of immunoglobulin A nephropathy in adults.

Inhalable nanovaccines offer needle-free, mucosal immunity against respiratory diseases like COVID-19, influenza, and TB. Explore delivery mechanisms, key technologies, and future breakthroughs.